ROLE OF DIABETES AND NONALCOHOLIC FATTY LIVER DISEASE FOR HCC DEVELOPMENT
DOI:
https://doi.org/10.52340/jecm.2022.717Keywords:
Hepatocellular carcinoma, Cirrhosis, α-fetoprotein, Diabetes mellitusAbstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. Despite advances in prevention techniques, screening, and new technologies in both diagnosis and treatment, incidence and mortality continue to rise. Cirrhosis remains the most important risk factor for the development of HCC regardless of etiology. Chronic medical conditions such as diabetes mellitus and obesity increase the risk of HCC. Diabetes mellitus directly affects the liver because of the essential role the liver plays in glucose metabolism. It can lead to chronic hepatitis, fatty liver, liver failure, and cirrhosis
Downloads
References
Center for Disease Control and Prevention (CDC). Hepatocellular carcinoma-United States 2001–2006. MMWR Morb Mortal Wkly Rep. 2010; 59(17):517–520.
Crissien AM, Frenette C. Current Management of hepatocellular carcinoma. Gastroenterol Hepatol. 2014;10(3):153–161.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2971.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–1491.
Gao C, Fang L, Zhao HC, Li JT, Yao SK. Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a crosssectional case-control study from Chinese patients with HBV infection. Hepatobiliary Pancreat Dis Int. 2013;12(4):385–393.
Turati F, Galeone C, Rota M, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol. 2014; 25(8):1526–1535.
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–2273.
Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639–1648.
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatol. 2014;59(6): 2188–2195.
El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systemic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369–380.
Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev. 1998;7(2):89–107.
Balkau B, Kahn H, Courbon D, Eschwege E, Ducimetiere P; Paris Prospective Study. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care. 2001;24(5):843–849.
Callee EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity and mortality from cancer in a prospective studied cohort of US adults. N Engl J Med. 2003;348:1625–1638.
Reddy JK, Rao MS. Lipid metabolism and liver inflammation. Am J Physiol Gastrointest Liver Physiol. 2006;290:G852–G858.
Larson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005–1008.
Monsour HP, Asham E, McFadden RS, Victor DW, Muthuswamy B, Zaheer I. Hepatocellular carcinoma: the rising tide from east to west – a review of epidemiology, screening and tumor markers. Transl Cancer Res. 2013;2(6):492–506.
Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, Hatakeyama, K. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. J Gastrointest Surg. 2011;15(8):1450–1458.
Tokushige K, Hashimoto E, Yatsuji S, et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45(9):960–967.
Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;7:1107–1115.
Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9(6):739–745.
Hagiwara S, Kudo M, Nagai T, et al. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer. 2012;106:1997–2003.
Au JS, Frenette CT. (2015). Management of hepatocellular carcinoma: current status and future directions. Gut Liver. 2015;9(4):437–448.
Imamura H, Matsuyama Y, Tanaka E. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–207.
Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19(42):7316–7326.
Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep. 2011;13(3):186–194.
Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. international trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer 2019 Oct 9. https://doi.
org/10.1002/ijc.32723. [Epub ahead of print]
Petrick JL, Campbell PT, Koshiol J, Thistle JE, Andreotti G,Beane-Freeman LE, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project. Br J Cancer 2018;118:1005-1012.
Ohkuma T, Peters SAE, Woodward M. Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia 2018;61:2140-2154.
Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology
2018;155:1828-1837.
Dai G, Liu P, Li X, Zhou X, He S. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: a meta-analysis. Medicine (Baltimore) 2019;98:e14324.
Kudo M. Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update. Liver Cancer. 2020;9 (6):640–662. doi:10.1159/000511001
Tsang J, Wong JSL, Kwok GGW, et al. Nivolumab + ipilimumab for patients with hepatocellular carcinoma previously treated with sorafenib. Expert Rev Gastroenterol Hepatol. 2021;1–10. Doi:10.1080/17474124.2021.1899808
Downloads
Published
How to Cite
Issue
Section
